Two-Year COMPARE Results Presented for Abbott Vascular's Xience V

September 23, 2010—Abbott Vascular (Santa Clara, CA) announced that Peter Smits, MD, presented late-breaking, 2-year data from the investigator-initiated COMPARE trial during the Transcatheter Cardiovascular Therapeutics scientific symposium Washington, DC.

According to Abbott Vascular, the COMPARE study is a physician-initiated, all-comers trial sponsored by Maasstad Ziekenhuis of Rotterdam, the Netherlands. The study is designed to reflect real-world, everyday clinical practice. COMPARE enrolled 1,800 patients in a single-center, prospective randomized (1:1) comparison of safety and efficacy of the Xience V stent to the Taxus Liberté stent (Boston Scientific Corporation, Natick, MA). The COMPARE trial was supported in part by a grant from Abbott Vascular. All aspects of the trial were designed and conducted independent of the company.

In the primary endpoint, the Xience V showed a 34% lower incidence of major adverse cardiac events (MACE)—death, nonfatal myocardial infarction (MI), and target vessel revascularization—at 2 years compared to the Taxus Liberté, (9% vs 13.7%; P = .0016). In the composite secondary endpoint of cardiac death, nonfatal MI, and target lesion revascularization, the Xience V resulted in a 35% lower incidence compared to the Taxus Liberté (7.4% vs 11.4%; P =.0038).

In addition, the Xience V demonstrated a 77% lower rate of stent thrombosis, defined as definite or probable according to Academic Research Consortium, versus the Taxus Liberté (0.9% vs 3.9%; P ≤ .0001); a 60% lower rate of target vessel revascularization (3.1% vs 7.7%; P ≤ .0001); a 56% lower rate of target lesion revascularization (2.6% vs 5.9%; P = .0005); and a 49% lower rate of nonfatal MI (3.9% vs 7.6%; P = .0009).

The stent thrombosis rate between 1 and 2 years increased from 0.7% to 0.9% for the Xience V and from 2.6% to 3.9% for the Taxus Liberté. At 2 years, 88.6% of Xience V patients and 84.8% of Taxus Liberté patients had discontinued dual-antiplatelet therapy, the company reported.